论文部分内容阅读
目的观察吉西他滨(泽菲)联合卡培他滨(希罗达)治疗乳腺癌肺转移患者的临床疗效和不良反应,为临床提供依据。方法 35例乳腺癌肺转移患者,用吉西他滨注射液1000 mg/(m2.d),第1,8天静脉点滴,卡培他滨1500 mg/(m2.d),分早晚2次餐后30 min口服,第1～14天,21 d为1个周期,连用2～6个周期,2个周期和6个周期评价疗效。结果 35例患者完全缓解(CR)11例(31.4%),部分缓解(PR)13例(37.1%)总有效率(CR+PR)为68.6%,稳定(SD)6例(17.1%),进展(PD)5例(14.3%)。不良反应主要是骨髓抑制、手足综合征和胃肠道反应,对症治疗后均获缓解。结论吉西他滨联合卡培他滨治疗肺转移性乳腺癌有较好疗效,不良反应能耐受,是一种安全有效的化疗方案。
Objective To observe the clinical efficacy and adverse reactions of gemcitabine (Zeflate) combined with capecitabine (Xeloda) in the treatment of patients with lung metastasis of breast cancer and provide the basis for clinical practice. Methods 35 cases of breast cancer patients with lung metastases, gemcitabine injection of 1000 mg / (m2.d), the first 1,8 days intravenous drip, capecitabine 1500 mg / (m2.d), points in the morning and evening after 2 meals 30 min orally, 1 to 14 days, 21 d for a cycle, even with 2 to 6 cycles, 2 cycles and 6 cycles evaluation of efficacy. Results The total effective rate (CR + PR) was 68.6% in 13 patients (37.1%) and 6 cases (17.1%) were stable (SD) in 35 patients with complete remission (CR) Progress (PD) in 5 cases (14.3%). Adverse reactions are mainly myelosuppression, hand-foot syndrome and gastrointestinal reactions, symptomatic treatment were relieved. Conclusion Gemcitabine combined with capecitabine is effective and safe in treating lung metastatic breast cancer. It is a safe and effective chemotherapy regimen.